Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFACED Sepsis
NCT05076435Phase 2Completed
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in sepsis (2 arms). Primary endpoint: 24-hour intravenous crystalloid fluid administration. Started Nov 2021; status: completed.
02
Conditions
sepsis
Beyond the preview
Go deeper on NCT05076435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076435.